- Company’s eTurna™ delivery platform ensures unprecedented precision, safety
- In-vivo biodistribution of mRNA into dermal cells, tissues shows high transfection efficiency, gene expression
- Data presented at ASDS Annual Meeting
Turn Biotechnologies, a cell rejuvenation developer of novel mRNA medicines for untreatable, age-related conditions, announced it is the first company to safely and specifically deliver mRNA in vivo in the skin without any off-target organ uptake.
The company used its eTurna lipid nanoparticle delivery platform to precisely reach in vivo dermal fibroblasts with an mRNA formulation. The eTurna-delivered formulation remained localized in the injection site and did not distribute to other organs.
Turn Biotechnologies is the first company to safely and specifically deliver mRNA in vivo in the skin without any off-target organ uptake.
Since the skin is the body’s natural layer of protection, delivering mRNA therapeutics within a lipid nanoparticle delivery system to a specific dermal target is a significant achievement. Researchers have delivered mRNA-based therapies to the lungs, spleen and liver, but no one has previously been able to target the dermal layer of the skin – the body’s largest organ.
“Being the first to deliver mRNA-based therapies so precisely in skin opens the door to drug therapies that have never before been possible,” said Turn Bio CEO Anja Krammer. “We are extremely excited about achieving another critical milestone on our path forward to the clinic.”
Turn Bio continues to expand the breakthrough capabilities of the eTurna delivery platform by developing a library of formulations and novel lipids to deliver high transfection efficiency and selectivity for target cell and tissue types, while maintaining low-to-no cytotoxicity and immunogenicity.
Turn Bio’s most recent research was shared at the American Society for Dermatologic Surgery Annual Meeting held Nov. 2-5 in Chicago.
“Turn Bio’s achievement is extremely exciting for dermatologic medicine as skin is the most challenging organ to treat effectively and safely,” said Dr. Amelia Hausauer, director of dermatology at Aesthetx Plastic Surgery and Dermatology in Campbell, California, and chair of the ASDS Regenerative Medicine Session. “It shows promise to significantly expand the therapies dermatologists can provide – and dramatically improve the quality of our patients’ lives.”
ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company’s proprietary mRNA-based ERA™ reprogramming technology restores optimal gene expression by combatting the effects of aging in the epigenome. This restores cells’ ability to prevent or treat disease and heal or regenerate tissue. It will help to fight incurable chronic diseases. Its eTurna™ delivery platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types.
The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system.
Check out our mRNA service to expedite your vaccine research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular...
Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
Recently, the France-based WIDGeT consortium emerged from a collaboration between Sanofi, WhiteLab Genomics, the TaRGeT Laboratory at Nantes University, and Institut Imagine. Scientists and companies in this consortium hope to speed up the development of gene...
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024...
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...